Guardant Health's Shield CRC Blood Test Achieves 95% Adherence Rate in Real-World Study of 20,000 Patients

Guardant Health announced new real-world data showing that its Shield blood-based screening test for colorectal cancer demonstrated patient adherence of 95% in a study of 20,000 patients. Shield is the first blood test to receive FDA approval as a primary screening option for CRC in average-risk adults aged 45 and older. The study found that Shield had an adherence rate of 98.5% in a separate study in Appalachia, increasing overall screening rates for CRC from 45% to 90%.